Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Other Accumulated Expenses (2016 - 2025)

Anaptysbio (ANAB) has disclosed Other Accumulated Expenses for 6 consecutive years, with $30.2 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Other Accumulated Expenses changed N/A year-over-year to $30.2 million, compared with a TTM value of $30.2 million through Dec 2024, changed N/A, and an annual FY2024 reading of $30.2 million, changed N/A over the prior year.
  • Other Accumulated Expenses was $30.2 million for Q4 2024 at Anaptysbio, up from $342000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $30.2 million in Q4 2024 and bottomed at $342000.0 in Q4 2020.